Intrynsic
Sign In
Sector HubStock AnalysisScreener
Sign InCreate Account
  1. Home
  2. /
  3. Stocks
  4. /
  5. Torrent Pharmaceuticals Limited

Healthcare · NSE: TORNTPHARM

Torrent Pharmaceuticals Limited - Fair Value & Intrinsic Value Estimate

Fair value estimate

Intrynsic's multi-model valuation estimates Torrent Pharmaceuticals Limited's fair value at ₹1,945 per share (range ₹1,945–₹2,119) against a market price of ₹4,669 (close of 17 Nov 2026): the estimate is 58% below the price. Estimate updated 17 November 2026. This is an estimated fair value based on stated assumptions, not investment advice.

Market price

₹4,669

close of 17 Nov 2026

Est. fair value

₹1,945

₹1,945–₹2,119

Estimate vs price

-58.4%

estimate below price

Price ₹4,669Fair value ₹1,945
Range ₹1,945–₹2,119

Above fair-value est.

Ask AI about TORNTPHARM

About Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals makes branded generic medicines, mainly for India, Brazil and Germany, with strength in heart and diabetes drugs. Growth in its Indian branded portfolio drives most of its profit.

Key numbers & health

Revenue
₹14.0K Cr

FY26

Net profit
₹2.1K Cr

FY26

EPS
₹63.92

FY26

Free cash flow
₹2.3K Cr

FY26

GrowthRevenue +13.3%/yr (3y) · +10.2%/yr (9y)Good

Over the last 3 years, revenue grew 13.3%/yr and profit grew 19.8%/yr. Over 9 years, revenue grew 10.2%/yr and profit 9.6%/yr.

ProfitabilityROE 25.5%Good

Every ₹100 of shareholder money earned ₹25.5 in profit last year, vs a sector median of 10.2%.

DebtD/E 1.79Weak

Debt is 1.79x shareholder equity and 3.0x yearly operating earnings — a heavy load.

Valuation-58% vs estimateWeak

The market price is above our estimated fair-value range (based on stated assumptions).

Quality₹144 cash per ₹100 profitGood

About ₹144 of every ₹100 of reported profit turned into free cash (median, last 5 years); operating cash flow was positive in 5 of 5 years.

Peers

Sun Pharmaceutical Industries Limited₹4,48,988 CrP/E 39.1ROE 13.8%Fair-value estimate →Divi's Laboratories Limited₹2,93,316 CrP/E 114.2ROE 15.3%Fair-value estimate →Cipla Limited₹1,14,487 CrP/E 29.5ROE 11.2%Fair-value estimate →
Ask AI about Torrent Pharmaceuticals LimitedChat with Intrynsic's research agent about results, risks and filings.Sign up free →Track it in your watchlistFair-value alerts, result-day briefs and portfolio analytics.Sign up free →See the full model workingsEvery assumption, per-model trace, reverse DCF and peer lens.Sign up free →

Frequently asked questions

What is Torrent Pharmaceuticals Limited's intrinsic value?

Intrynsic's multi-model valuation estimates Torrent Pharmaceuticals Limited's fair value at ₹1,945 per share (range ₹1,945–₹2,119), last updated 17 November 2026. This is an estimate based on stated assumptions, not investment advice.

Is Torrent Pharmaceuticals Limited overvalued or undervalued?

Torrent Pharmaceuticals Limited trades at ₹4,669 against Intrynsic's estimated fair value of ₹1,945 - the market price is 58% above the estimate, i.e. above our estimated fair-value range. Different assumptions produce different estimates; see the model breakdown above.

What is Torrent Pharmaceuticals Limited's P/E ratio?

Torrent Pharmaceuticals Limited trades at about 73.0 times its latest annual earnings per share.

What does Torrent Pharmaceuticals Limited do?

Torrent Pharmaceuticals makes branded generic medicines, mainly for India, Brazil and Germany, with strength in heart and diabetes drugs. Growth in its Indian branded portfolio drives most of its profit.

How is Torrent Pharmaceuticals Limited's fair value calculated?

Intrynsic runs 2 valuation models for Torrent Pharmaceuticals Limited (EV/EBITDA, P/E Multiple) and blends them into one estimated fair-value range. Every assumption - growth, discount rate, terminal value - is shown openly on this page.

Disclaimer: Intrynsic provides educational and informational analysis only. Fair-value figures are estimates based on stated assumptions- they are not investment advice, research recommendations, or an offer to transact in any security. The models rely on assumptions (discount rates, growth, multiples) that may prove wrong and on past financials, which do not guarantee future results; prices also move on macro factors the models don't capture. Intrynsic is not a SEBI-registered investment adviser or research analyst. Markets carry risk; please do your own research or consult a registered adviser before making investment decisions. Prices shown may be delayed end-of-day values. Terms · Privacy

Intrynsic

Indian Equity Research Assistant. Built for serious investors.

Research

  • Sector Hub
  • Stock Analysis
  • Screener
  • Videos
  • IV Calculator
  • Spotlight
  • Market Signals
  • Macro Analysis
  • News
  • Announcements
  • AI Research
  • Watchlist
  • Portfolio

Product

  • Features
  • How it Works
  • About
  • Plans
  • FAQ
  • Compare
  • Blog
  • Knowledge Base

Legal

  • Privacy Policy
  • Terms of Service

Support

  • Contact Us
  • How it Works

Stay Updated

Get the latest news and updates delivered to your inbox.

Enter your emailEnter your email

© 2026–27 Intrynsic. All rights reserved.
Intrynsic is a product of FINTERVUE.IO Private Limited.
For informational purposes only. Not investment advice.

Built with ♥ for India